Blujepa

Blujepa Warnings and Precautions

• QTc prolongation: Blujepa should be avoided in patients with a history of QTc prolongation, relevant cardiac disease, or those taking other QTc-prolonging medicines.
• Hypersensitivity reactions: Anaphylaxis and other allergic reactions have been reported.
• Renal impairment: Should be avoided in patients with severe renal impairment (eGFR less than 30 mL/min), including dialysis patients.
• Hepatic impairment: Should be avoided in patients with severe hepatic impairment (Child-Pugh Class C).
• Gastrointestinal effects: Diarrhea and nausea are common; taking with food can help reduce GI upset.

How to Access Blujepa in India: A 6-Step Process

Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.

Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.

Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.

Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.

Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant conditions to maintain product integrity.

Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.

Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.

Documentation & Availability

What documents are required to import Blujepa to India?

Blujepa (gepotidacin) tablets may be imported in the patient's name only, by patients or government hospitals, in line with India's import regulations for unapproved medicines. The following documentation is required:

• A valid prescription from a qualified physician
• The patient's diagnostic reports confirming an uncomplicated urinary tract infection
• Patient ID proof (issued by the Government of India)

How is the order confirmed?

The order is confirmed only after receipt and verification of a valid prescription from the doctor and, if applicable, an import permit.

Is Blujepa available in India?

Blujepa (gepotidacin tablets) is a prescription medicine that legally requires a doctor's prescription to be dispensed. As of current publicly available information, Blujepa is not commercially marketed in India.

However, patients in India can legally access Blujepa through the Named Patient Program (NPP) — an import provision that allows patients to receive medicines approved in other countries but not yet marketed in India, under a doctor's prescription and proper regulatory documentation.

Blujepa received US FDA approval in 2026 for uncomplicated urinary tract infections in female patients, ensuring full transparency throughout the process.

Blujepa can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others.

Sourcing & Delivery of Blujepa

Blujepa is sourced directly from authorized channels in the country of origin and shipped to India under GDP-compliant logistics to preserve product integrity from dispatch to delivery.

• Storage maintained at 15°C to 30°C throughout transit
• Real-time shipment tracking and delivery updates
• Delivery coordinated directly with the patient, family, or treating hospital

Availability of Blujepa Across Major Cities in India

Named Patient Program supports access to Blujepa for patients with uncomplicated urinary tract infections across major cities in India, coordinating documentation, sourcing, and delivery with treating physicians.

Mumbai

Patients in Mumbai can access Blujepa through NPP with support from treating physicians and urologists.

Delhi

In Delhi, NPP coordinates with hospitals and specialty clinics to facilitate timely access to Blujepa.

Bangalore

Bangalore's urology and general medicine centers work with NPP to support patients requiring Blujepa.

Chennai

Patients in Chennai can access Blujepa through NPP, with coordination between treating doctors and the program's regulatory and logistics team.

Hyderabad

Hyderabad's urology centers support diagnosis and access coordination for Blujepa through NPP.

Kolkata

NPP facilitates access to Blujepa for patients in Kolkata under the guidance of treating physicians.

Pune

Patients in Pune can access Blujepa through NPP with prescription-based coordination and delivery support.

Ahmedabad

NPP supports access to Blujepa for patients in Ahmedabad, working directly with treating specialists.

Kochi

Patients in Kochi and across Kerala can access Blujepa through NPP's regulated import pathway.

Chandigarh

NPP coordinates access to Blujepa for patients in Chandigarh and the surrounding region.

Jaipur

Patients in Jaipur can access Blujepa through NPP with support from treating physicians.

Lucknow

NPP facilitates access to Blujepa for patients in Lucknow and across Uttar Pradesh.

Bhubaneswar

Patients in Bhubaneswar can access Blujepa through NPP's coordinated import and delivery process.

Guwahati

NPP supports access to Blujepa for patients in Guwahati and across the Northeast region.

NPP also supports access for patients in other Indian cities not listed above — contact the team to check availability and timelines for your location.